 OSAKA, Japan CAMBRIDGE, Mass.--BUSINESS WIRE--Takeda Pharmaceutical Company Limited TSE:4502NYSE:TAK Takeda today announced that the U.S. Food and Drug Administration FDA has approved EXKIVITY mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer NSCLC with epidermal growth factor receptor EGFR exon 20 insertion mutations as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemo 